A prospective, randomized, double‐blind, multicentre, parallel‐group, active controlled study to compare efficacy and safety of biosimilar adalimumab (Exemptia;<scp>ZRC</scp>‐3197) and adalimumab (Humira) in patients with rheumatoid arthritis